BioView News
11 articles
/PRNewswire/ -- BioView Ltd. (TASE: BIOV), a company developing advanced medical imaging systems for cancer cell detection, traded on the Tel Aviv Stock...
BioView Ltd., a company specializing in medical imaging systems for cancer detection, announced the completion of the first stage of a joint project with a UK partner. The project focuses on developing a liquid biopsy test to detect HER2 genetic amplification and protein expression in circulating tumor cells from metastatic breast cancer patients. This innovative test offers a safer and more comprehensive alternative to traditional tissue biopsies. The study presented at the AACR International Liquid Biopsy Conference showed promising results, identifying HER2-positive patients who were initially classified as HER2-negative. This advancement could significantly improve treatment decisions and patient outcomes. Dr. Chassidy Johnson, Chief Scientist at BioView, emphasized the tests potential in identifying patients for advanced HER2-targeted therapies.
Partners
ביו ויו מוותרת על המיזוג עם אומגה; תקנה מניות של עצמה - דווקא כשעלו
ביו ויו מוותרת על המיזוג עם אומגה ומכינה תוכנית לרכישה עצמית של מניות בשווי 2 מיליון שקל. החברה נמצאת במאבק שליטה ומתמודדת עם סימני חולשה בשוק העבודה. מחיר המניה עלה ב-25% מתחילת השנה. ביו ויו עדכנה כי המיזוג עם אומגה ירד מהפרק והיא מתכננת לרכוש מניות עצמית.
PartnersExpand
הפיכת חצר בביו ויו: השקיעו 10 מיליון שקל והשתלטו על חברה בשווי 60 מיליון | כלכליסט
After a six-month control struggle, Shir Chen has taken over BioView, a company specializing in the development, production, and marketing of computerized imaging systems for early cancer detection. The companys general assembly of shareholders approved the replacement of the existing directors with Chens team. The company, which is traded on the Tel Aviv Stock Exchange at a value of NIS 60 million, is expected to undergo significant changes under Chens leadership, although the direction of these changes has not yet been publicly detailed.
Management Changes
אומגה מתכוננת ליום שאחרי הקורונה ומנסה להיכנס לבורסה על ידי מיזוג כלכליסט
Omega, a company that operates a laboratory for decoding coronavirus tests, is preparing for a post-coronavirus future and trying to enter the stock market by merging with Bio View, a company traded on the Tel Aviv Stock Exchange with a market value of 52 million shekels. The value of the merged company in the deal is 300 million shekels. Omega is interested in the merger so that it can expand into areas other than coronavirus testing.
AcquisitionExpand
ביו ויו חתמה על הסכם הפצה לשיווק ומכירת מערכות באיחוד האמירויות ובחריין
BioView, a company specializing in the research, development, marketing, and sale of computerized systems for identifying abnormal cells in various fields and developing new tests that assist in cancer detection, has signed a distribution agreement with Dubai-based GlobalMedHub. The agreement is exclusive and will be in effect for a period of 5 years. The partnership is part of BioViews plans to expand into new markets and create new growth engines in addition to the markets in which the company operates.
PartnersExpand
ANGLE to present results from recent collaboration on circulating tumor cells at Molecular Med Tri-Con 2020 Conference
RSIP Vision and BioView Collaborate, Using Artificial Intelligence to Classify Chromosomes for Highly Accurate Genetic Testing Results
RSIP Vision has collaborated with BioView to use artificial intelligence for chromosome classification in genetic testing, reducing time and expense. The AI solution improves accuracy and provides faster results for patients. RSIP Vision has also announced other AI-based solutions for lung segmentation and knee replacement surgery. BioView has implemented the AI solution in its Duet Image and Analysis systems at leading hospitals in the USA and Europe, receiving positive feedback from clinical operators. RSIP Vision is a global leader in AI, computer vision, and image processing technology, while BioView develops and supplies cell imaging equipment and analysis software.
Customers
BioView signs Chinese distribution deal worth NIS 70m
BioView Ltd. has signed a substantial cooperation agreement in China with Livzon Cynvenio Diagnostics to market its imaging systems as part of a blood-test product for early detection of lung cancer. The agreement will result in orders worth at least NIS 70 million over five years. The announcement caused BioViews share price to soar 30% and reach a market cap of NIS 44 million. The partnership with Livzon Cynvenio Diagnostics, a joint venture of Livzon Pharmaceuticals and Cynvenio, will help penetrate the Chinese market and develop new tests for diagnosis, monitoring, and treatment.
PartnersCustomers
Vortex Biosciences and BioView Announce Collaboration to Develop Integrated Workflow for Clinical Biomarker Identification on Circulating Tumor Cells
Vortex Biosciences and BioView Ltd. have announced a collaboration to develop an integrated workflow for identifying clinical biomarkers on circulating tumor cells (CTCs). The collaboration aims to create a workflow for the isolation and characterization of CTCs to provide clinical insights to physicians. Vortex Biosciences VTX-1 Liquid Biopsy System automates the isolation of CTCs from whole blood, while BioViews Duet imaging system and proprietary CTC analysis algorithm automate the identification and biomarker analysis of CTCs on a glass slide. The integrated workflow is currently being used in several clinical studies focused on CTC enumeration, ALK FISH rearrangements, and PD-L1 expression on CTCs. The collaboration aims to move the characterization of CTCs into the clinical market.
Partners
FDA approves BioView lung cancer scanning system
BioView Ltd. has received FDA approval for its Duet scanning system for detecting mutations in lung cancer patients. The companys share price increased by 18.7% on the Tel Aviv Stock Exchange. The approval will allow BioView to penetrate the pathology lab market and position itself as a world leader. Lung cancer has the highest mortality rate worldwide, with over 250,000 new diagnoses and 160,000 deaths annually in the US.
Customers
BioView, Abbott extend cancer diagnostics collaboration
BioView has signed a cooperation agreement with Abbott Molecular to develop an automated cancer screening system for Abbotts lung cancer diagnostic test. The current manual test will be automated, saving time and effort and improving accuracy. BioView has previously applied its technology to other Abbott Molecular tests, which boosted sales. The two companies will conduct clinical trials to certify the automated lung cancer test for marketing in the US. The process is expected to take several months.
Partners
